News

ISOThrive Awarded Composition of Matter and Production Method Patent for its First “Farmaceutical™” to Support Animal Health

ISOThrive Inc., a microbiome therapeutics company announced that the U.S. Patent and Trademark Office has issued a Composition of Matter and Production Method patent for its first Farmaceutical™ Maltosyl-Isomaltooligosaccharides (MIMO™), a prebiotic for use as an animal feed additive and pet food supplement. USDA and University of GA studies showed MIMO as highly effective at protecting chickens against antibiotic resistant Salmonella while improving feed efficiency.

ISOThrive opens up a whole new market opportunity to offer higher quality meats that are free of pathogens and also leaner. At the same time, increased food safety is better for workers, less costly for producers and better for the environment. Plus, there are emerging opportunities in pet health with supplements that support better digestion with less reliance on medications.

The widespread use of antibiotics in cattle, swine and chickens can lead to the creation of antibiotic resistant bacterial species.  The same antibiotics used in animal feed are also used to treat disease in humans. With the rise of antibiotic resistant bacteria, eliminating their use in livestock has become a necessity. Prebiotics, while offering a viable alternative to antibiotics, can be expensive to manufacture. This patent covers an economical and efficient method for making (MIMO) that can be used as an additive for animal feed at significantly lower cost.

“Today’s conscious consumer wants a healthier food supply, a better environment for the people that produce the food and has the least amount of environmental impact,” said Jack Oswald, ISOThrive’s CEO, CTO and Co-Founder. “This new patent allows us to open a new market opportunity while simultaneously positively impacting food safety and security at a cost that makes sense for producers.”

Researchers at USDA and University of Georgia found that MIMO added to chicken feed reduced antibiotic resistant Salmonella by 99% while increasing Bifidobacteria.  Feed efficiency was increased by 9-10%.

 

Recent News

07/14/2025

Nanochon Announces Health Canada Approval for First in Human Investigation

Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant for treating articular cartilage defects in the knee, is thrilled to announce that it was granted Health Canada approval for their first in human clinical trial. The trial will be led by Principal Investigator, Dr. Fathi Abuzgaya, who will collaborate with

07/14/2025

Terumo Health Outcomes Announces Distribution Agreement for Caretaker Medical’s VitalStream® Non-Invasive Hemodynamic Monitoring

Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), today announced a new U.S. distribution agreement with Caretaker Medical to offer Caretaker Medical’s VitalStream wearable hemodynamic monitoring platform to hospitals nationwide. This agreement is yet another step in THO’s continued effort to bring forward-looking technologies to cardiovascular care teams seeking smarter, more efficient

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive